Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study

Hunter Wessells, Kevin Fuciarelli, John Hansen, Mac E. Hadley, Victor J Hruby, Robert T Dorr, Norman Levine

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Purpose: We evaluated the erectogenic properties of a new cyclic α-melanocyte-stimulating hormone analogue, Melanotan-II, to treat men with psychogenic erectile dysfunction. Materials and Methods: Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan- II and a vehicle placebo were compared using real-time RigiScan monitoring. The presence, duration and rigidity of erections were recorded during a 6-hour period. Results: In 8 of 10 men treated with Melanotan-II clinically apparent erections developed. Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p = 0.0045). Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment. Conclusions: Melanotan- II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.

Original languageEnglish (US)
Pages (from-to)389-393
Number of pages5
JournalJournal of Urology
Volume160
Issue number2
DOIs
StatePublished - Aug 1998

Fingerprint

Erectile Dysfunction
Cross-Over Studies
Placebos
Peptides
Yawning
Melanocyte-Stimulating Hormones
Appetite
Nausea
melanotan-II
Injections

Keywords

  • MSH
  • Penile erection

ASJC Scopus subject areas

  • Urology

Cite this

Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction : Double-blind, placebo controlled crossover study. / Wessells, Hunter; Fuciarelli, Kevin; Hansen, John; Hadley, Mac E.; Hruby, Victor J; Dorr, Robert T; Levine, Norman.

In: Journal of Urology, Vol. 160, No. 2, 08.1998, p. 389-393.

Research output: Contribution to journalArticle

Wessells, Hunter ; Fuciarelli, Kevin ; Hansen, John ; Hadley, Mac E. ; Hruby, Victor J ; Dorr, Robert T ; Levine, Norman. / Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction : Double-blind, placebo controlled crossover study. In: Journal of Urology. 1998 ; Vol. 160, No. 2. pp. 389-393.
@article{67011dd8d48d4817ae2b0e158d6f4080,
title = "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study",
abstract = "Purpose: We evaluated the erectogenic properties of a new cyclic α-melanocyte-stimulating hormone analogue, Melanotan-II, to treat men with psychogenic erectile dysfunction. Materials and Methods: Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan- II and a vehicle placebo were compared using real-time RigiScan monitoring. The presence, duration and rigidity of erections were recorded during a 6-hour period. Results: In 8 of 10 men treated with Melanotan-II clinically apparent erections developed. Mean duration of tip rigidity greater than 80{\%} was 38.0 minutes with Melanotan-II and 3.0 with placebo (p = 0.0045). Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment. Conclusions: Melanotan- II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.",
keywords = "MSH, Penile erection",
author = "Hunter Wessells and Kevin Fuciarelli and John Hansen and Hadley, {Mac E.} and Hruby, {Victor J} and Dorr, {Robert T} and Norman Levine",
year = "1998",
month = "8",
doi = "10.1016/S0022-5347(01)62903-3",
language = "English (US)",
volume = "160",
pages = "389--393",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction

T2 - Double-blind, placebo controlled crossover study

AU - Wessells, Hunter

AU - Fuciarelli, Kevin

AU - Hansen, John

AU - Hadley, Mac E.

AU - Hruby, Victor J

AU - Dorr, Robert T

AU - Levine, Norman

PY - 1998/8

Y1 - 1998/8

N2 - Purpose: We evaluated the erectogenic properties of a new cyclic α-melanocyte-stimulating hormone analogue, Melanotan-II, to treat men with psychogenic erectile dysfunction. Materials and Methods: Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan- II and a vehicle placebo were compared using real-time RigiScan monitoring. The presence, duration and rigidity of erections were recorded during a 6-hour period. Results: In 8 of 10 men treated with Melanotan-II clinically apparent erections developed. Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p = 0.0045). Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment. Conclusions: Melanotan- II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.

AB - Purpose: We evaluated the erectogenic properties of a new cyclic α-melanocyte-stimulating hormone analogue, Melanotan-II, to treat men with psychogenic erectile dysfunction. Materials and Methods: Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan- II and a vehicle placebo were compared using real-time RigiScan monitoring. The presence, duration and rigidity of erections were recorded during a 6-hour period. Results: In 8 of 10 men treated with Melanotan-II clinically apparent erections developed. Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p = 0.0045). Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment. Conclusions: Melanotan- II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.

KW - MSH

KW - Penile erection

UR - http://www.scopus.com/inward/record.url?scp=0032323804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032323804&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)62903-3

DO - 10.1016/S0022-5347(01)62903-3

M3 - Article

C2 - 9679884

AN - SCOPUS:0032323804

VL - 160

SP - 389

EP - 393

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -